Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/19/2018 |
| Start Date: | August 22, 2018 |
| End Date: | March 1, 2021 |
| Contact: | Yuting P Chiang, M.D. |
| Email: | ypc2@duke.edu |
| Phone: | 919-970-5318 |
The purpose of this study is to determine the utility of tricuspid valve repair at the time
of LVAD implantation for patients presenting with moderate or severe tricuspid regurgitation.
The study will be a randomized trial for patients presenting for LVAD implantation to either
tricuspid valve repair or no tricuspid valve repair. The data will be analyzed as both an
intention to treat analysis as well as an "as treated" analysis with the primary outcome
being rates of right ventricular dysfunction post LVAD implantation. Tricuspid valve repair
for these patient is currently being done for some patients, without any strong data to
either support such practice or negate it.
of LVAD implantation for patients presenting with moderate or severe tricuspid regurgitation.
The study will be a randomized trial for patients presenting for LVAD implantation to either
tricuspid valve repair or no tricuspid valve repair. The data will be analyzed as both an
intention to treat analysis as well as an "as treated" analysis with the primary outcome
being rates of right ventricular dysfunction post LVAD implantation. Tricuspid valve repair
for these patient is currently being done for some patients, without any strong data to
either support such practice or negate it.
This study is a prospective, single center, randomized trial. Up to 280 subjects will be
enrolled.
Inclusion Criteria - Potential subjects must meet all inclusion criteria to participate.
- Planned LVAD implantation (either destination or bridge indication)
- 18 years of age or older
- Patients wilith mild tricuspid regurgitation (TR) during surgical planning will be
screened for meeting inclusion criteria for this study.
- TR on pre-operative echo (within one week of procedure) (TTE or intraoperative TEE)
quantified as moderate or severe with normal tricuspid valve leaflets
Exclusion Criteria
- Previous tricuspid valve surgery
- Previous LVAD
- Planned concurrent right ventricular assist device (RVAD) or extracorporeal membrane
oxygenation (ECMO) at the time of LVAD operation or during the same hospitalization
- Preimplant RVAD or ECMO
- Planned thoracotomy approach for LVAD implantation
- Pregnant women
All subjects will undergo an intraoperative transesophageal echocardiogram (TEE) to evaluate
their tricuspid valve. Subjects will be randomized in the operating room. Randomization will
be stratified based on preoperative right ventricle dysfunction. Subjects will be randomized
1:1 to either of the following treatment arms:
- Study arm (Arm A) - Tricuspid valve ring annuloplasty or replacement at the time of LVAD
implantation plus medical therapy
- Control arm (Arm B) - LVAD implantation plus medical therapy (the medical therapy
involved includes inotropic medications and diuretic medications, which are standard of
care for patients in this population)
Subjects will be monitored in the surgical and on the step down floor ICU, and follow-up data
will be collected on subjects monthly from routine tests and clinic visits. This will include
information on adverse events and any hospital readmissions, a quality of life questionnaire
at their 6 month visit, and a six minute walk test at three and 6 months.
enrolled.
Inclusion Criteria - Potential subjects must meet all inclusion criteria to participate.
- Planned LVAD implantation (either destination or bridge indication)
- 18 years of age or older
- Patients wilith mild tricuspid regurgitation (TR) during surgical planning will be
screened for meeting inclusion criteria for this study.
- TR on pre-operative echo (within one week of procedure) (TTE or intraoperative TEE)
quantified as moderate or severe with normal tricuspid valve leaflets
Exclusion Criteria
- Previous tricuspid valve surgery
- Previous LVAD
- Planned concurrent right ventricular assist device (RVAD) or extracorporeal membrane
oxygenation (ECMO) at the time of LVAD operation or during the same hospitalization
- Preimplant RVAD or ECMO
- Planned thoracotomy approach for LVAD implantation
- Pregnant women
All subjects will undergo an intraoperative transesophageal echocardiogram (TEE) to evaluate
their tricuspid valve. Subjects will be randomized in the operating room. Randomization will
be stratified based on preoperative right ventricle dysfunction. Subjects will be randomized
1:1 to either of the following treatment arms:
- Study arm (Arm A) - Tricuspid valve ring annuloplasty or replacement at the time of LVAD
implantation plus medical therapy
- Control arm (Arm B) - LVAD implantation plus medical therapy (the medical therapy
involved includes inotropic medications and diuretic medications, which are standard of
care for patients in this population)
Subjects will be monitored in the surgical and on the step down floor ICU, and follow-up data
will be collected on subjects monthly from routine tests and clinic visits. This will include
information on adverse events and any hospital readmissions, a quality of life questionnaire
at their 6 month visit, and a six minute walk test at three and 6 months.
Inclusion Criteria:
- Planned LVAD implantation (either destination or bridge indication)
- 18 years of age or older
- Patients will mild tricuspid regurgitation (TR) during surgical planning will be
screened for meeting inclusion criteria for this study.
- Patients with moderate or graeter TR on pre-operative echo (within one week of
procedure) (TTE or intraoperative TEE) will qualify for randomization
Exclusion Criteria:
- Previous tricuspid valve surgery
- Previous left ventricular assist device
- Planned concurrent right ventricular assist device (RVAD) or extracorporeal membrane
oxygenation (ECMO) at the time of LVAD operation or during the same hospitalization
- Preimplant RVAD or ECMO
- Pregnant women
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
